Product/Service

BioDrugs

Source: Adis International Inc.
BioDrugs is a journal that healthcare decision makers can turn to for succinct and comprehensive coverage of current
BioDrugs - Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy

Introduction
BioDrugs is a journal that healthcare decision makers can turn to for succinct and comprehensive coverage of current and future biotechnology drugs and immunomodulatory agents, as well as the current and future implications of genomics and gene therapy.

In BioDrugs you'll find:
  • Original Research Articles: rapid publication of the latest clinical trials.
  • Current Opinion and Leading Articles: short reviews of controversial and emerging areas.
  • Disease Management Articles: reviews of practical clinical relevance to today's immune-based disease management, containing important treatment guidelines and comparisons of available agents.
  • Review Articles: provide excellent reference, research and educational material in immunopharmacology and immune-disease management.
  • Adis Drug Evaluations: a state-of-the-art combination of scientific evaluation, practical relevance and independent credibility - the place of drugs in immune-based disease therapy.
  • Adis New Drug Profiles: - easy-to-read literature reviews plus expert commentaries on biotechnology and immunomodulatory agents in late phase development.

    • Aims and Scope
    BioDrugs provides healthcare decision makers with a regular programme of peer reviewed articles covering issues in the clinical application of biotechnological and immunological knowledge to the treatment of human disease.
    The Journal includes:
    • Leading/current opinion articles providing an overview of contentious or emerging issues
    • Definitive reviews on a broad range of topics in biopharmaceuticals, gene therapy and clinical immunology, including the development and optimum therapeutic use of agents based on biotechnological and immunological principles and the treatment of disorders with an immunological component
    • Disease management reviews including recommendations for specific clinical situations
    • Adis Drug Evaluations reviewing the properties and place in therapy of both newer and established drugs
    • Adis New Drug Profiles with expert commentary
    • Original research articles on the human clinical pharmacology, clinical development and therapeutic optimisation of relevant drugs will also be considered for publication.
    All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication. Please contact us at biodrugs@adis.co.nz.

    Adis International Inc., 860 Town Center Drive, Langhorne, PA 19047. Tel: 215-741-5200; Fax: 215-741-5282.